The Science Behind the Sacrament

Research Rooted in Reputable Institutions

Lōkahi Sanctuary's approach is grounded in a growing body of clinical research from some of the world's leading institutions. Here's what the science actually says.

The Science of Sacred Healing

For centuries, Indigenous peoples have known what science is only beginning to confirm: these medicines heal. The growing body of clinical research into psilocybin, ayahuasca, and other entheogens represents some of the most exciting and promising work in modern medicine. At Lōkahi Sanctuary, we take this science seriously — not because we need it to validate what we already know in our hearts and bodies, but because it matters that the world understands what is possible

The Scale of the Problem

40+

MILLION

People are diagnosed with anxiety disorder

over 20

PERCENT

Of adults are struggling with their mental health — and the number is rising.

21+

MILLION

Americans suffer from
major depression

57%

OF PARTICIPANTS

Receiving psilocybin therapy achieved remission after 6 weeks — compared with 28% taking a leading antidepressant.

What the Research Is Exploring

The modern study of psilocybin is one of the most active frontiers in mental health research. Across leading institutions, scientists are investigating how these medicines may support healing — with the strongest evidence to date in depression, anxiety, and end-of-life distress, and promising early work in other areas. The science is young and evolving, and not every avenue below is equally established. What unites them is a growing body of researchers taking these ancient medicines seriously, and studying them with rigor.

01 — Depression & Anxiety

Including treatment-resistant depression

02 — PTSD & Trauma

Helping process trauma and reduce symptoms

03 — Addictions

Alcohol, nicotine, opioids, and more

04 — End-of-Life Distress

Easing existential distress and death anxiety

05 — Bipolar Disorder

Studied for depression and mood stability

06 — ADD & ADHD

Supporting focus, attention, and regulation

07 — Tinnitus

Early research shows promise for relief

08 — Chronic Conditions

Exploring benefits across a range of conditions

These represent areas of active and early-stage research, not established treatments or medical claims. Psilocybin is not appropriate for everyone — some conditions, including bipolar disorder and a history of psychosis, may make it unsafe. Nothing here is medical advice. Thorough screening and professional guidance are essential.

Beyond Relief

The Quiet Expansion

Healing isn't only about easing what weighs us down. Many who work with these medicines describe something more expansive — a return to the fuller, more alive version of themselves.

Focus & Creative Flow

A mind that feels clearer and more open — sharper attention, and ideas that move freely.

Mental Stamina

Renewed cognitive flexibility and the resilience to meet daily demands without depletion.

Joy & Peace

Not fleeting happiness, but a quieter, steadier contentment that tends to linger.

Connection

A felt sense of belonging — to yourself, to the people around you, and to the world itself.

These are not promises. They are the experiences people return to us with, again and again — the quiet ways this work ripples outward, long after a session ends.

FEATURED CLINICAL STUDIES

Three Institutions Leading the Research

Johns Hopkins Center for Psychedelic & Consciousness Research

Johns Hopkins was the first U.S. institution to launch a dedicated center for psychedelic research. Their trials on psilocybin-assisted therapy for major depressive disorder have shown rapid, durable improvements in mood and outlook for a majority of participants.

NYU Langone Health

NYU's psilocybin research has focused heavily on end-of-life anxiety and depression in patients with life-threatening cancer diagnoses, along with alcohol use disorder — with results showing significant, sustained reductions in symptoms after guided sessions.

Imperial College London — Centre for Psychedelic Research

Imperial's landmark head-to-head trial compared psilocybin therapy directly against a leading SSRI antidepressant (escitalopram). Psilocybin performed as well as the antidepressant on core depression measures — and outperformed it on secondary measures of wellbeing, meaning, and connection.